TCGA-85-8287-01A-11R-2296-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INTERFERON_ALPHA_RESPONSE+0.450
- MITOTIC_SPINDLE+0.430
- WNT_BETA_CATENIN_SIGNALING+0.430
- INTERFERON_GAMMA_RESPONSE+0.410
- TGF_BETA_SIGNALING+0.410
- ANGIOGENESIS+0.370
- APICAL_SURFACE+0.360
- UV_RESPONSE_DN+0.350
- TNFA_SIGNALING_VIA_NFKB+0.330
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- FATTY_ACID_METABOLISM-0.370
- CHOLESTEROL_HOMEOSTASIS-0.280
- PANCREAS_BETA_CELLS-0.280
- MTORC1_SIGNALING-0.270
- XENOBIOTIC_METABOLISM-0.270
- ADIPOGENESIS-0.240
- PEROXISOME-0.220
- GLYCOLYSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296078 | — | cohortSQ1 | 0.882 |
| 2 | SRR8613802 | — | D | 0.851 |
| 3 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.842 |
| 4 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.831 |
| 5 | 57f2cc66-9163-4e07-93f8-d5a2158e7125 | — | — | 0.829 |
| 6 | TCGA-34-5239-01A-21R-1820-07 | — | cohortSQ1 | 0.825 |
| 7 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.817 |
| 8 | TCGA-DQ-7592-01A-11R-2081-07 | — | — | 0.812 |
| 9 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.809 |
| 10 | TCGA-BH-A18I-01A-11R-A12D-07 | — | A | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |